Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Map2k6 is a potent genetic modifier of arterial rupture in vascular Ehlers-Danlos syndrome mice
Caitlin J. Bowen, Rebecca Sorber, Juan Francisco Calderón Giadrosic, Jefferson J. Doyle, Graham Rykiel, Zachary Burger, Xiaoyan Zhang, Wendy A. Espinoza Camejo, Nicole Anderson, Simone Sabnis, Chiara Bellini, Elena Gallo MacFarlane, Harry C. Dietz
Caitlin J. Bowen, Rebecca Sorber, Juan Francisco Calderón Giadrosic, Jefferson J. Doyle, Graham Rykiel, Zachary Burger, Xiaoyan Zhang, Wendy A. Espinoza Camejo, Nicole Anderson, Simone Sabnis, Chiara Bellini, Elena Gallo MacFarlane, Harry C. Dietz
View: Text | PDF
Research Article Cardiology Genetics Vascular biology

Map2k6 is a potent genetic modifier of arterial rupture in vascular Ehlers-Danlos syndrome mice

  • Text
  • PDF
Abstract

Aortic dissection or rupture is a major cause of mortality in vascular Ehlers-Danlos syndrome (vEDS), a connective tissue disorder caused by heterozygous mutations in the collagen type III alpha 1 chain (COL3A1) gene. C57BL6/J (BL6) mice carrying the Col3a1G938D/+ mutation recapitulate the vEDS vascular phenotype and die suddenly of aortic rupture/dissection. However, 129S6/SvEvTac (referred to here as 129) mice expressing the same Col3a1G938D/+ mutation show near-complete lifelong protection from vascular rupture. To identify genetic modifiers of vascular risk in vEDS, we performed genome-wide genotyping of intercrossed BL6/129 vEDS mice stratified by survival and identified a significant protective locus encompassing a variant in Map2k6, encoding mitogen-activated protein kinase kinase 6 (M2K6), a p38-activating kinase. Genetic ablation of Map2k6 rendered previously protected 129 vEDS mice susceptible to aortic rupture, in association with reduced protein phosphatase 1 activity and increased PKC and ERK phosphorylation. Accelerated vascular rupture in vEDS mice treated with a pharmacological inhibitor of p38 was rescued by concomitant ERK antagonism, supporting an opposing role for ERK and p38 in the modification of aortic rupture risk in vEDS. These results suggest that pharmacologic strategies aimed at mimicking the effect of this natural protective pathway may attenuate aortic rupture risk in vEDS.

Authors

Caitlin J. Bowen, Rebecca Sorber, Juan Francisco Calderón Giadrosic, Jefferson J. Doyle, Graham Rykiel, Zachary Burger, Xiaoyan Zhang, Wendy A. Espinoza Camejo, Nicole Anderson, Simone Sabnis, Chiara Bellini, Elena Gallo MacFarlane, Harry C. Dietz

×

Figure 4

Inhibition of p38 activation increases the risk of vascular rupture in BL6 vEDS mice.

Options: View larger image (or click on image) Download as PowerPoint
Inhibition of p38 activation increases the risk of vascular rupture in B...
(A) Kaplan-Meier survival curve comparing saline-injected BL6 vEDS mice (n = 19, 7 female and 12 male) with BL6 vEDS mice (n = 14, 6 females and 8 males) receiving SB203580 (p38 inhibitor) via intraperitoneal injection and SB203580-treated also receiving cobimetinib, a MEK inhibitor (n = 14, 6 females and 8 males), starting at postnatal day 21 and continuing for 40 days thereafter. Significant differences were calculated using log-rank (Mantel-Cox) analysis (** P < 0.01, *** P < 0.001). (B) Immunoblot of aortic lysates from the proximal descending thoracic aortas of BL6 vEDS mice treated with placebo or p38 inhibitor at 45 days of age, probed with antibodies directed for p-PKCβ and p-ERK and quantification of immunoblot. Each symbol represents an independent biological replicate, with unfilled symbols representing male samples. Error bars show mean ± SEM. P value refers to unpaired t test with Welch’s correction (** P < 0.01). Red circles represent placebo-treated mice, and blue squares represent p38 inhibitor–treated mice. (C) Summary figure outlining contributors to risk of vascular rupture in the aorta of vEDS mouse models.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts